OPKO Health (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 150,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 150,000 shares of the business’s stock in a transaction that occurred on Friday, October 31st. The stock was bought at an average cost of $1.42 per share, for a total transaction of $213,000.00. Following the completion of the purchase, the chief executive officer owned 214,386,448 shares of the company’s stock, valued at $304,428,756.16. This trade represents a 0.07% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, August 8th, Phillip Md Et Al Frost acquired 675,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.32 per share, for a total transaction of $891,000.00.

OPKO Health Price Performance

OPKO Health stock opened at $1.36 on Friday. The stock’s 50 day moving average is $1.46 and its 200 day moving average is $1.38. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The firm has a market cap of $1.08 billion, a P/E ratio of -5.44 and a beta of 1.50. OPKO Health, Inc. has a one year low of $1.11 and a one year high of $2.04.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. The company had revenue of $151.67 million for the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The firm’s quarterly revenue was down 12.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 earnings per share. As a group, research analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on OPK shares. LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Jefferies Financial Group reissued a “hold” rating and issued a $1.60 price target (down from $2.00) on shares of OPKO Health in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research note on Wednesday, October 8th. Wall Street Zen raised OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Saturday. Finally, Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $2.28.

Institutional Investors Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of OPKO Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company’s stock valued at $48,970,000 after acquiring an additional 293,740 shares in the last quarter. Sculptor Capital LP bought a new stake in shares of OPKO Health during the first quarter valued at approximately $21,111,000. Geode Capital Management LLC increased its holdings in shares of OPKO Health by 23.7% during the second quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock valued at $13,763,000 after acquiring an additional 1,995,633 shares in the last quarter. Millennium Management LLC increased its holdings in shares of OPKO Health by 39.2% during the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after acquiring an additional 1,798,385 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of OPKO Health by 4.2% during the first quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock valued at $6,642,000 after acquiring an additional 161,394 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.